RxDoctor Payments DataLook up a doctor →

Warren Chumley, MD

Clinical Neurophysiology · Lexington, KYNPI 1902853617

Payments from drug & device makers

$648,355in general payments, 2019–2025

Across 1,242 payments — averaging $522.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$278K
  • AbbVie$166K
  • Amgen$45K
  • Genentech, Inc.$34K
  • F. Hoffmann-la Roche AG$30K
  • Teva Pharmaceuticals USA, Inc.$27K
  • plus $69K from 53 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Sanofi35$277,637
AbbVie(2 entities)430$165,838
Amgen61$45,484
Genentech, Inc.6$33,771
F. Hoffmann-la Roche AG5$29,915
Teva Pharmaceuticals USA, Inc.121$26,566
Lilly USA, LLC69$16,760
Biohaven Pharmaceuticals, Inc.31$11,889
Biohaven Pharmaceutical Holding Company Ltd.51$9,033
Lundbeck LLC11$5,580
Mallinckrodt Enterprises LLC11$4,487
AstraZeneca23$4,422
Axsome Therapeutics, Inc.4$4,004
Eli Lilly2$3,313
Sunovion Pharmaceuticals Inc.17$1,890
Novartis57$1,177
Pfizer101$1,020
Biogen22$797
Eisai Inc.13$527
EMD Serono, Inc.12$401
UCB, Inc.19$395
Bristol Myers Squibb11$383
Acadia Pharmaceuticals Inc10$305
Vanda Pharmaceuticals Inc.11$276
SK Life Science, Inc.6$249
CSL Behring8$238
Neurocrine Biosciences, Inc.5$215
Genentech USA, Inc.16$202
Takeda Pharmaceuticals U.S.A., Inc.8$179
Jazz Pharmaceuticals Inc.7$142
Sanofi-aventis U.S. LLC4$134
Novo Nordisk1$119
Amneal Pharmaceuticals LLC5$91
Avanir Pharmaceuticals, Inc.5$84
Azurity Pharmaceuticals, Inc.4$77
Merz North America, Inc.3$68
TG Therapeutics, Inc.3$62
Argenx US, Inc.3$60
Akcea Therapeutics, Inc.2$52
Merz Pharmaceuticals, LLC2$49
Grifols USA, LLC2$48
MDD US Operations, LLC3$46
Promius Pharma LLC3$39
Boston Scientific2$36
Johnson & Johnson2$34
Arbor Pharmaceuticals, Inc.2$31
Catalyst Pharmaceuticals, Inc.1$28
Otsuka America Pharmaceutical, Inc.1$25
Octapharma USA, Inc.1$22
ANI Pharmaceuticals, Inc.1$20
Livanova USA, Inc.1$18
Cala Health, Inc.1$17
Acorda Therapeutics, Inc1$17
Vertical Pharmaceuticals, LLC1$16
Upsher-smith Laboratories LLC1$16
Neuronetics, Inc.1$13
Aprecia Pharmaceuticals, LLC1$13
Zyla Life Sciences, Inc.1$13
Supernus Pharmaceuticals, Inc.1$12

How this compares

Too few clinical neurophysiology providers in Kentuckyto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$263,974
Medicare patients
204
Services billed
30,087

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other clinical neurophysiology in Lexington

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →